TIDMAPH
RNS Number : 4606M
Alliance Pharma PLC
12 January 2023
For immediate release 12 January 2023
ALLIANCE PHARMA
("Alliance", "Company" or the "Group")
Senior Management and Board Update
Appointment of COO to drive strategic growth in consumer
healthcare
Alliance Pharma plc (AIM: APH), the international healthcare
group, announces the appointment of a Chief Operating Officer to
strengthen the executive team and Board of Directors, and to
support the delivery of the Company's growth strategy which is
focused on consumer health. The Group also provides an update on
the return to the business of Peter Butterfield, the Chief
Executive Officer.
Chief Operating Officer ("COO")
Jeyan Heper will join Alliance as COO and Board member on 1
February 2023. Jeyan has a strong track record of strategic
leadership in the international consumer health market, overseeing
a number of global programs and driving growth in flagship brands.
In his career spanning more than 24 years Jeyan has held senior
executive roles in brand management at Procter & Gamble and
marketing at Danone Group. In addition, Jeyan was President and
General Manager of Ansell's sexual wellness global business before
it was spun-out to become Lifestyles Healthcare, a private
equity/pharma-owned company where Jeyan became CEO.
During his tenure as CEO at Lifestyles Healthcare, Jeyan
delivered significant growth through market and category expansion,
building a strong e-commerce platform in China and the US, and
improving operational effectiveness. Most recently, Jeyan worked as
Head of Global Transformation at British American Tobacco ("BAT")
leading the development and execution of the strategy to broaden
the company's reach into non-nicotine consumer products. Following
BAT's minority investment in NASDAQ-listed Organigram Inc., Jeyan
became a member of the Organigram board.
The role of COO will bolster the Group's operational
capabilities, identify growth opportunities, and drive further the
Company's strategy to expand its consumer health presence.
Update on Chief Executive Officer ("CEO")
Peter Butterfield, CEO, is expected to commence his return to
the business in Q1 2023 on a phased basis. To assist Peter's return
and to strengthen further the executive team, the Board has decided
to appoint an interim CEO who is expected to join the Board. The
interim CEO will focus primarily on strategic delivery and external
stakeholder engagement, is expected to remain with Alliance
throughout the upcoming appeal hearing at the Competition Appeal
Tribunal, which is scheduled to commence on 5 June 2023, and will
hand-back to Peter thereafter. The recruitment process is well
underway and a further update will be provided in due course.
David Cook, Chair of Alliance, said :
"I am delighted that Jeyan is joining Alliance. The Company has
grown and developed significantly since I became Chair, building an
international footprint with a strong portfolio of consumer
healthcare brands. The appointment of a COO will ensure that the
organisational structure is appropriate for the future of the
business . Jeyan will bring significant additional expertise from
the global consumer healthcare sector to keep the Company well
positioned to deliver continued growth over the longer term.
"We very much look forward to welcoming Peter back to Alliance,
the Board believes that the appointment of the interim CEO will
help to make his return seamless."
Save as disclosed below, the Company confirms that there are no
further disclosures to be made in relation to Rule 17 of paragraph
(g) of Schedule Two of the AIM Rules for Companies in respect of
Jeyan Heper's appointment to the Alliance Board.
Mr Jeyan Heper, aged 49, does not currently hold any
directorships but has held the following in the past five
years:
Directorships in the past five Lifestyles Healthcare Pte Ltd
years: Organigram Holdings Inc (Canada)
Sxwell UK Limited (UK)
Unimil Sp. z o.o20 (Poland)
Lifestyles Europe SAS (France)
Ansell Healthcare Europe NV
(Belgium)
SXWell Belgium BV (Belgium)
Mr Heper does not hold any ordinary shares of 1 pence each in
the Company.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations
& Corporate Communications + 44 (0)1249 705168
ir@allianceph.com
+ 44 (0)20 7466
Buchanan 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
+ 44 (0)20 7260
Numis Securities Limited 1000
Nominated Adviser: Freddie Barnfield / Duncan
Monteith
Corporate Broking: James Black
+ 44 (0)20 7597
Investec Bank plc 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group. Our purpose is to improve the lives of consumers and
patients through making available a range of clinically valuable
healthcare products.
Our core focus is on the marketing of Consumer Healthcare
brands, complemented by a smaller Prescription Medicines business.
In total, we hold marketing rights to around 80 brands, with
revenues generated from a mix of direct, distributor and e-commerce
sales.
Headquartered in the UK, the Group employs around 250 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics
operations, we remain asset-light and focused on maximising the
value of our brands.
For more information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASFIEFFEDSEFF
(END) Dow Jones Newswires
January 12, 2023 02:00 ET (07:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024